Bennett Julian Named Vice President of New Business Development for Solvay Pharmaceuticals, Inc.
Marietta, Ga. (September 28, 2006) – Bennett (Ben) P. Julian has been named vice president of new business development for Solvay Pharmaceuticals, Inc. In this role, Julian assumes primary responsibility for all business development activities for the company.
Julian holds an M.B.A. in marketing and international business from the University of Chicago and earned a B.Sc. degree in finance from Indiana University. Prior to joining Solvay Pharmaceuticals, he was with Baxter Healthcare Corporation for seven years, most recently as vice president of business strategy, planning and development for the company’s Anesthesia, Critical Care & Oncology Division, where he led global business development and strategic planning activities. Prior to Baxter Healthcare Corporation, he worked with OHMEDA INC./THE BOC GROUP for nine years, serving in a variety of roles including the director of licensing and business development for its pharmaceuticals unit. Julian started his career at Abbott Laboratories, holding financial and business analyst positions during his five years with the company.
"Ben Julian is a critical addition to our business development team," said Laurence Downey, M.D., president and CEO of Solvay Pharmaceuticals, Inc. "He will help the company evaluate potential U.S. pharmaceutical product acquisitions compatible with our business strategy and lead our team in seeking licensing opportunities. Ben will also take on an important global role by leading Solvay Pharmaceuticals' neuroscience business development worldwide."
About Solvay Pharmaceuticals, Inc.
Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, specialized markets and men’s and women’s health. Its 2005 sales were EUR 2.3 billion and it employs approximately 10,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
Solvay is an international chemical and pharmaceutical group with headquarters in Brussels. It employs some 30,000 people in 50 countries. In 2005 its consolidated sales amounted to EUR 8.6 billion, generated by its three activity sectors: Chemicals, Plastics and Pharmaceuticals. SOLVAY (Euronext : SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. Details are available at www.solvay.com.
